Aytu BioPharma Inc. (NASDAQ:AYTU) Receives Average Recommendation of “Hold” from Analysts

Aytu BioPharma Inc. (NASDAQ:AYTU) has been given an average recommendation of “Hold” by the five ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $9.3333.

Several brokerages have issued reports on AYTU. Wall Street Zen raised Aytu BioPharma to a “hold” rating in a research note on Saturday, February 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Wednesday, April 8th. Finally, Zacks Research raised Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th.

Institutional Investors Weigh In On Aytu BioPharma

Several hedge funds have recently added to or reduced their stakes in the company. Diadema Partners LP lifted its stake in Aytu BioPharma by 12.1% during the fourth quarter. Diadema Partners LP now owns 305,788 shares of the company’s stock worth $795,000 after purchasing an additional 33,118 shares during the last quarter. Persistent Asset Partners Ltd lifted its stake in Aytu BioPharma by 27.2% during the fourth quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock worth $206,000 after purchasing an additional 16,963 shares during the last quarter. Two Sigma Investments LP lifted its stake in Aytu BioPharma by 96.2% during the third quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock worth $129,000 after purchasing an additional 33,701 shares during the last quarter. Arete Wealth Advisors LLC bought a new stake in Aytu BioPharma during the first quarter worth about $135,000. Finally, Dimensional Fund Advisors LP lifted its stake in Aytu BioPharma by 23.3% during the first quarter. Dimensional Fund Advisors LP now owns 43,585 shares of the company’s stock worth $119,000 after purchasing an additional 8,222 shares during the last quarter. Institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Price Performance

NASDAQ:AYTU opened at $2.18 on Wednesday. The firm has a market capitalization of $23.40 million, a price-to-earnings ratio of -0.48 and a beta of 0.28. Aytu BioPharma has a 52-week low of $1.46 and a 52-week high of $3.07. The stock has a fifty day moving average of $2.50 and a 200 day moving average of $2.44. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.00 and a current ratio of 1.12.

Aytu BioPharma (NASDAQ:AYTU) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.09). The business had revenue of $12.41 million for the quarter, compared to the consensus estimate of $12.05 million. Aytu BioPharma had a negative net margin of 60.17% and a negative return on equity of 69.93%. On average, research analysts expect that Aytu BioPharma will post -0.69 EPS for the current fiscal year.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.